Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleBasic Science Investigation

Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy

Viviane J. Tschan, Sarah D. Busslinger, Peter Bernhardt, Pascal V. Grundler, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli and Cristina Müller
Journal of Nuclear Medicine October 2023, 64 (10) 1625-1631; DOI: https://doi.org/10.2967/jnumed.123.265524
Viviane J. Tschan
1Center for Radiopharmaceutical Sciences ETH–PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah D. Busslinger
1Center for Radiopharmaceutical Sciences ETH–PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Bernhardt
2Department of Radiation Physics, Institution of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal V. Grundler
1Center for Radiopharmaceutical Sciences ETH–PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan Rijn Zeevaart
3Radiochemistry, South African Nuclear Energy Corporation (Necsa), Brits, South Africa;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulli Köster
4Institut Laue-Langevin, Grenoble, France;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas P. van der Meulen
1Center for Radiopharmaceutical Sciences ETH–PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland;
5Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Schibli
1Center for Radiopharmaceutical Sciences ETH–PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland;
6Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cristina Müller
1Center for Radiopharmaceutical Sciences ETH–PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland;
6Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 64 no. 10 1625-1631
DOI 
https://doi.org/10.2967/jnumed.123.265524
PubMed 
37442604

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication January 28, 2023
  • Revision received May 31, 2023
  • Published online October 3, 2023.

Article Versions

  • previous version (July 13, 2023 - 06:50).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Viviane J. Tschan*,1,
  2. Sarah D. Busslinger*,1,
  3. Peter Bernhardt2,
  4. Pascal V. Grundler1,
  5. Jan Rijn Zeevaart3,
  6. Ulli Köster4,
  7. Nicholas P. van der Meulen1,5,
  8. Roger Schibli1,6 and
  9. Cristina Müller1,6
  1. 1Center for Radiopharmaceutical Sciences ETH–PSI, Paul Scherrer Institute, Villigen-PSI, Switzerland;
  2. 2Department of Radiation Physics, Institution of Clinical Science, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden;
  3. 3Radiochemistry, South African Nuclear Energy Corporation (Necsa), Brits, South Africa;
  4. 4Institut Laue-Langevin, Grenoble, France;
  5. 5Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen-PSI, Switzerland; and
  6. 6Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland
  1. For correspondence or reprints, contact Cristina Müller (cristina.mueller{at}psi.ch).
  1. ↵* Contributed equally to this work.

View Full Text

Statistics from Altmetric.com

Cited By...

  • 16 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics
    Cristina Müller, Nicholas P. van der Meulen, Roger Schibli
    European Journal of Nuclear Medicine and Molecular Imaging 2023 50 11
  • Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes
    Matteo Corpetti, Cristina Müller, Himisha Beltran, Johann de Bono, Jean-Philippe Theurillat
    European Urology 2024 85 3
  • PSMA and Sigma-1 receptor dual-targeted peptide mediates superior radionuclide imaging and therapy of prostate cancer
    Zhenyuan Huangfu, Jiangtao Yang, Juan Sun, Bin Xu, Lei Tao, Jiang Wu, Feng Wang, Guanglin Wang, Fenghua Meng, Zhiyuan Zhong
    Journal of Controlled Release 2024 375
  • Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma
    Michael D. Pun, Fabio Gallazzi, Khanh-Van Ho, Lisa Watkinson, Terry L. Carmack, Ejike Iweha, Longbo Li, Carolyn J. Anderson
    Molecular Pharmaceutics 2024 21 6
  • Opportunities and challenges for targeted radionuclide therapy of prostate cancer using 161Tb
    C. Morgat, M. Van de Voorde, S. Bodin, C. Champion, E. Hindié
    Médecine Nucléaire 2023 47 6
  • First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study
    Alin Chirindel, Guillaume P. Nicolas, Frida Westerbergh, Lisa McDougall, David E. Schmid, Susanne Geistlich, Viviane J. Tschan, Sarah D. Busslinger, Angelique Fokkema, Nicola Aceto, Peter Bernhardt, Nicholas P. van der Meulen, Cristina Müller, Damian Wild, Roger Schibli
    European Journal of Nuclear Medicine and Molecular Imaging 2025 52 5
  • Harnessing the power of f-block elements in radiopharmaceuticals
    Alex Rigby, Trevor Arino
    Nature Reviews Chemistry 2024 8 5
  • Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer
    Philipp Ritt, René Fernández, Cristian Soza-Ried, Heinz Nicolai, Horacio Amaral, Korbinian Krieger, Ana Katrina Mapanao, Amanda Rotger, Konstantin Zhernosekov, Roger Schibli, Cristina Müller, Vasko Kramer
    European Journal of Nuclear Medicine and Molecular Imaging 2025
  • Highlight selection of radiochemistry and radiopharmacy developments by editorial board
    S. Spreckelmeyer, J. Dasilva, C. Decristoforo, R. H. Mach, J. Passchier, G. Carlucci, M. Al Qhatani, A. Duatti, B. T. Cornelissen, J. Engle, A. Denkova, J. J. M. A. Hendrikx, Y. Seimbille, X. Yang, H. Jia, M-R. Zhang, M. Yang, L. Perk, P. Caravan, P. Laverman, Z. Cheng, C. Hoehr, T. Sakr, J. R. Zeevaart
    EJNMMI Radiopharmacy and Chemistry 2025 10 1
  • Is Copper-61 the New Gallium-68? Automation and Preclinical Proof-of-Concept of 61Cu-Based Radiopharmaceuticals for Prostate Cancer Imaging
    Diana Rodrigues, Alexandra I. Fonseca, Sérgio do Carmo, José Sereno, Ivanna Hrynchak, João N. Moreira, Célia Gomes, Antero Abrunhosa
    Pharmaceuticals 2025 18 4

Article usage

Article usage: July 2023 to April 2025

AbstractFullPdf
Jul 2023145910169
Aug 20237419460
Sep 20233524621
Oct 202391814764
Nov 202319425874
Dec 202315712148
Jan 202421417856
Feb 20248029881
Mar 20245620265
Apr 20244218180
May 20245127853
Jun 20243017657
Jul 20243730179
Aug 202422244178
Sep 20243512363
Oct 20243614073
Nov 20243315377
Dec 20242315573
Jan 20251913485
Feb 20252523587
Mar 20252118898
Apr 202527191122
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 64 (10)
Journal of Nuclear Medicine
Vol. 64, Issue 10
October 1, 2023
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy
Viviane J. Tschan, Sarah D. Busslinger, Peter Bernhardt, Pascal V. Grundler, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli, Cristina Müller
Journal of Nuclear Medicine Oct 2023, 64 (10) 1625-1631; DOI: 10.2967/jnumed.123.265524

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Albumin-Binding and Conventional PSMA Ligands in Combination with 161Tb: Biodistribution, Dosimetry, and Preclinical Therapy
Viviane J. Tschan, Sarah D. Busslinger, Peter Bernhardt, Pascal V. Grundler, Jan Rijn Zeevaart, Ulli Köster, Nicholas P. van der Meulen, Roger Schibli, Cristina Müller
Journal of Nuclear Medicine Oct 2023, 64 (10) 1625-1631; DOI: 10.2967/jnumed.123.265524
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Visual Abstract
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Designed Ankyrin Repeat Protein–Mediated Peptide Nucleic Acid–Based Pretargeting: A Proof-of-Principle Study
  • [11C]ZTP-1: An Effective Short-Lived Radioligand for PET of Rat and Monkey Brain Phosphodiesterase Type 4 Subtype B
  • Reduced Renal Uptake of Various Radiopharmaceuticals with Sodium Paraaminohippurate Coadministration in a Rat Model
Show more Basic Science Investigation

Similar Articles

Keywords

  • PSMA
  • prostate cancer
  • 161Tb
  • albumin-binding radioligand
  • radioligand therapy
SNMMI

© 2025 SNMMI

Powered by HighWire